UC2288

UC2288 is a potent and orally active p21 attenuator (relatively selective activity for p21), which is synthesized based Sorafenib (HY-10201) . UC2288 potently inhibits cancer cell growth by inducing apoptosis. UC2288 has no inhibition of VEGFR2 and Raf kinases even at 10 μM[1].

Product Specifications

CAS Number

[1394011-91-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; MDM-2/p53

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/uc2288.html

Purity

99.82

Solubility

DMSO : 50 mg/mL (ultrasonic) |Ethanol : 12.5 mg/mL (ultrasonic)

Smiles

O=C(N[C@H]1CC[C@H](OC2=NC=C(C(F)(F)F)C=C2)CC1)NC3=CC=C(Cl)C(C(F)(F)F)=C3

Molecular Formula

C20H18ClF6N3O2

Molecular Weight

481.82

Precautions

H302, H315, H319, H335

References & Citations

[1]Hiromi I Wettersten, et al. A Novel p21 Attenuator Which Is Structurally Related to Sorafenib. Cancer Biol Ther. 2013 Mar;14 (3) :278-85.|[2]Romi Gupta, et al. Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A. Proc Natl Acad Sci U S A. 2014 Jul 29;111 (30) :E3062-71.|[3]Jun Hyung Im, et al. p21 inhibitor UC2288 ameliorates MPTP induced Parkinson’s disease progression through inhibition of oxidative stress and neuroinammation. Translational Medicine.Neurobiology of Disease